Oncolytic Virotherapy as Promising Immunotherapy Against Cancer: Mechanisms of Resistance to Oncolytic Viruses

References

• Bray F , FerlayJ, SoerjomataramIet al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer68(6), 394–424 (2018).
   Web of Science ®Google Scholar
• Kaufman HL , BommareddyPK. Two roads for oncolytic immunotherapy development. J. Immunother. Cancer7(1), 26 (2019).
   PubMedGoogle Scholar
• Andtbacka RH , KaufmanHL, CollichioFet al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol.33(25), 2780–2788 (2015).
   PubMed Web of Science ®Google Scholar
• Kaufman HL , AndtbackaRHI, CollichioFAet al. Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. J. Immunother. Cancer5(1), 72 (2017).
   PubMedGoogle Scholar
• Hamid O , HoffnerB, GasalEet al. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunol. Immunother.66(10), 1249–1264 (2017).
   PubMed Web of Science ®Google Scholar
• Zhang ZL , ZouWG, LuoCXet al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res.13(6), 481–489 (2003).
   PubMed Web of Science ®Google Scholar
• Qi R , GuJ, ZhangZet al. Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis. Cancer Gene Ther.14(1), 82–90 (2007).
   PubMed Web of Science ®Google Scholar
• Goradel NH , MohajelN, MalekshahiZVet al. Oncolytic adenovirus: a tool for cancer therapy in combination with other therapeutic approaches. J. Cell. Physiol.234(6), 8636–8646 (2019).
   PubMed Web of Science ®Google Scholar
• Goradel NH , NegahdariB, GhorghanluSet al. Strategies for enhancing intratumoral spread of oncolytic adenoviruses. Pharmacol. Ther.213, 107586 (2020).
   PubMed Web of Science ®Google Scholar
• Dock G . The influence of complicating diseases upon leukaemia. Am. J. Med. Sci.127(4), 563 (1904).
   Google Scholar
• Csatary L . Viruses in the treatment of cancer. Lancet298(7728), 825 (1971).
   Google Scholar
• Smith RR , HuebnerRJ, RoweWPet al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer9(6), 1211–1218 (1956).
   PubMed Web of Science ®Google Scholar
• Okuno Y , AsadaT, YamanishiKet al. Studies on the use of mumps virus for treatment of human cancer. Biken J.21(2), 37–49 (1978).
   PubMedGoogle Scholar
• Murray DR , CasselWA, TorbinAHet al. Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer40(2), 680–686 (1977).
   PubMed Web of Science ®Google Scholar
• Pasquinucci G . Possible effect of measles on leukaemia. Lancet1(7690), 136 (1971).
   PubMed Web of Science ®Google Scholar
• Bierman HR , CrileDM, DodKSet al. Remissions in leukemia of childhood following acute infectious disease. Staphylococcus and streptococcus, varicella, and feline panleukopenias. Cancer6(3), 591–605 (1953).
   PubMed Web of Science ®Google Scholar
• Bluming A , ZieglerJ. Regression of Burkitt's lymphoma in association with measles infection. Lancet.2(7715), 105–106 (1971).
   PubMed Web of Science ®Google Scholar
• Taqi AM , AbdurrahmanMB, YakubuAM, FlemingAF. Regression of Hodgkin's disease after measles. Lancet317(8229), 1112 (1981).
   Google Scholar
• Melcher A , ParatoK, RooneyCM, BellJC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol. Ther.19(6), 1008–1016 (2011).
   PubMed Web of Science ®Google Scholar
• Liang M . Oncorine, the world first oncolytic virus medicine and its update in China. Curr. Cancer Drug Targets18(2), 171–176 (2018).
   PubMed Web of Science ®Google Scholar
• Dobner T , HorikoshiN, RubenwolfS, ShenkT. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science272(5267), 1470–1473 (1996).
   PubMed Web of Science ®Google Scholar
• Lu W , ZhengS, LiX-F, HuangJ-J, ZhengX, LiZ. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J. Gastroenterol.10(24), 3634 (2004).
   PubMed Web of Science ®Google Scholar
• Doniņa S , StrēleI, ProbokaGet al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res.25(5), 421 (2015).
   PubMed Web of Science ®Google Scholar
• Hennessy ML , BommareddyPK, BolandG, KaufmanHL. Oncolytic immunotherapy. Surg. Oncol. Clin.28(3), 419–430 (2019).
   PubMed Web of Science ®Google Scholar
• Raja J , LudwigJM, GettingerSNet al. Oncolytic virus immunotherapy: future prospects for oncology. J. Immunother. Cancer6(1), 140 (2018).
   PubMedGoogle Scholar
• Agarwalla PK , AghiMK. Oncolytic herpes simplex virus engineering and preparation. Methods Mol. Biol.797, 1–19 (2012).
   PubMedGoogle Scholar
• Tanaka R , GoshimaF, EsakiSet al. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model. Am. J. Cancer Res.7(8), 1693 (2017).
   PubMed Web of Science ®Google Scholar
• Uchida H , MarzulliM, NakanoKet al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol. Ther.21(3), 561–569 (2013).
   PubMed Web of Science ®Google Scholar
• Ghouse SM , NguyenH-M, BommareddyPKet al. Oncolytic herpes simplex virus encoding IL12 controls triple-negative breast cancer growth and metastasis. Front. Oncol.10, 384 (2020).
   PubMed Web of Science ®Google Scholar
• Luo Y , LinC, RenWet al. Intravenous injections of a rationally selected oncolytic herpes virus as a potent virotherapy for hepatocellular carcinoma. Mol. Ther.15, 153–165 (2019).
   Web of Science ®Google Scholar
• Martuza RL , MalickA, MarkertJMet al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science252(5007), 854–856 (1991).
   PubMed Web of Science ®Google Scholar
• Bommareddy PK , PatelA, HossainS, KaufmanHL. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am. J. Clin. Dermatol.18(1), 1–15 (2017).
   PubMed Web of Science ®Google Scholar
• Rehman H , SilkAW, KaneMP, KaufmanHL. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J. Immunother. Cancer4(1), 53 (2016).
   PubMedGoogle Scholar
• Patel DM , ForemanPM, NaborsLBet al. Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Hum. Gene Ther. Clin. Dev.27(2), 69–78 (2016).
   PubMed Web of Science ®Google Scholar
• Chiocca EA , NakashimaH, KasaiKet al. Preclinical toxicology of rQNestin34. 5v. 2: An oncolytic herpes virus with transcriptional regulation of the ICP34. 5 neurovirulence gene. Mol. Ther. Clin. Dev.17, 871–893 (2020).
   PubMed Web of Science ®Google Scholar
• Wang J-N , HuP, ZengM-S, LiuR-B. Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin. J. Cancer30(12), 831 (2011).
   PubMedGoogle Scholar
• Bhattacharjee S , YadavaPK. Measles virus: background and oncolytic virotherapy. Biochem. Biophys. Rep.13, 58–62 (2018).
   PubMedGoogle Scholar
• Msaouel P , OpyrchalM, DispenzieriAet al. Clinical trials with oncolytic measles virus: current status and future prospects. Curr. Cancer Drug Targets18(2), 177–187 (2018).
   PubMed Web of Science ®Google Scholar
• Hutzen B , RaffelC, StudebakerAW. Advances in the design and development of oncolytic measles viruses. Oncolytic virother.4, 109–118 (2015).
   PubMedGoogle Scholar
• Peng K-W , FacteauS, WegmanTet al. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med.8(5), 527–531 (2002).
   PubMed Web of Science ®Google Scholar
• Duprex WP , McQuaidS, HangartnerLet al. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J. Virol.73(11), 9568–9575 (1999).
   PubMed Web of Science ®Google Scholar
• Duprex WP , RimaBK. Using green fluorescent protein to monitor measles virus cell-to-cell spread by time-lapse confocal microscopy. Methods. Mol. Biol.183, 297–307 (2002).
   PubMedGoogle Scholar
• Riesco-Eizaguirre G , SantistebanP. A perspective view of sodium iodide symporter research and its clinical implications. Eur. J. Endocrinol.155(4), 495–512 (2006).
   PubMed Web of Science ®Google Scholar
• Ghanaat M , GoradelNH, ArashkiaAet al. Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer. Acta Pharmacol. Sin.doi: 10.1038/s41401-021-00616-5 (2021).
   PubMed Web of Science ®Google Scholar
• Abudoureyimu M , LaiY, TianCet al. Oncolytic adenovirus – a nova for gene-targeted oncolytic viral therapy in HCC. Front. Oncol.9, 1182 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang KJ , ZhangJ, WuYMet al. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression. Cancer Gene Ther.19(9), 619–629 (2012).
   PubMed Web of Science ®Google Scholar
• Rodriguez R , SchuurER, LimHYet al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res.57(13), 2559–2563 (1997).
   PubMed Web of Science ®Google Scholar
• Nemunaitis J , TongAW, NemunaitisMet al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol. Ther.18(2), 429–434 (2010).
   PubMed Web of Science ®Google Scholar
• Kuryk L , MøllerA-SW, JaderbergM. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology8(2), e1532763 (2019).
   PubMed Web of Science ®Google Scholar
• Packiam VT , LammDL, BarocasDAet al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Urol. Oncol.36(10), 440–447 (2018).
   PubMed Web of Science ®Google Scholar
• Hemminki O , DosSantos JM, HemminkiA. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol.13(1), 1–15 (2020).
   PubMed Web of Science ®Google Scholar
• Kim JH , OhJY, ParkBHet al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther.14(3), 361–370 (2006).
   PubMed Web of Science ®Google Scholar
• Hengstschläger M , PfeilstöckerM, WawraE. Thymidine kinase expression: a marker for malignant cells. Clin. Biochem.3(30), 294 (1997).
   Google Scholar
• Zhang Q , YongAY, WangEet al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res.67(20), 10038–10046 (2007).
   PubMed Web of Science ®Google Scholar
• Lauer U , ZimmermannM, SturmJet al. Phase I/II clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 in patients with unresactable, chemotherapy-resistant peritoneal carcinomatosis. J. Clin. Oncol.31(Suppl. 15), 3098 (2013).
   Web of Science ®Google Scholar
• Shafren DR , AuGG, NguyenTet al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin. Cancer Res.10(1), 53–60 (2004).
   PubMed Web of Science ®Google Scholar
• Skelding KA , BarryRD, ShafrenDR. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res. Treat.113(1), 21–30 (2009).
   PubMed Web of Science ®Google Scholar
• Au GG , LinczLF, EnnoA, ShafrenDR. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br. J. Haematol.137(2), 133–141 (2007).
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI , CurtiB, HallmeyerS, FengZ, PaustianC, BifulcoC. Phase II CALM extension study: enhanced immune-cell infiltration within the tumour micro-environment of patients with advanced melanoma following intralesional delivery of Coxsackievirus A21. Eur J Cancer51, S677 (2015).
   Web of Science ®Google Scholar
• Bradley S , JakesAD, HarringtonK, PandhaH, MelcherA, Errington-MaisF. Applications of coxsackievirus A21 in oncology. Oncolytic virother.3, 47 (2014).
   PubMedGoogle Scholar
• Schirrmacher V . Fifty years of clinical application of Newcastle disease virus: time to celebrate!Biomedicines4(3), 16 (2016).
   PubMedGoogle Scholar
• Zamarin D , PaleseP. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol.7(3), 347–367 (2012).
   PubMed Web of Science ®Google Scholar
• Fournier P , WildenH, SchirrmacherV. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int. J. Oncol.40(1), 287–298 (2012).
   PubMed Web of Science ®Google Scholar
• Wilden H , FournierP, ZawatzkyR, SchirrmacherV. Expression of RIG-I, IRF3, IFN-β and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virus. Int. J. Oncol.34(4), 971–982 (2009).
   PubMed Web of Science ®Google Scholar
• Holl EK , BrownMC, BoczkowskiDet al. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget7(48), 79828 (2016).
   PubMedGoogle Scholar
• Mahalingam D , GoelS, AparoSet al. A phase II study of pelareorep (REOLYSIN®) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma. Cancers (Basel)10(6), 160 (2018).
   PubMed Web of Science ®Google Scholar
• Mahalingam D , FountzilasC, MoseleyJet al. A phase II study of REOLYSIN®(pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother. Pharmacol.79(4), 697–703 (2017).
   PubMed Web of Science ®Google Scholar
• Philbrick BD , AdamsonDC. Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. Expert Opin. Investig. Drugs28(3), 207–216 (2019).
   PubMed Web of Science ®Google Scholar
• Hogan DJ , ZhuJ-J, DiagoORet al. Molecular analyses support the safety and activity of retroviral replicating vector Toca 511 in patients. Clin. Cancer Res.24(19), 4680–4693 (2018).
   PubMed Web of Science ®Google Scholar
• Harrington K , FreemanDJ, KellyBet al. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov.18(9), 689–706 (2019).
   PubMed Web of Science ®Google Scholar
• Marabelle A , AndtbackaR, HarringtonKet al. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann. Oncol.29(11), 2163–2174 (2018).
   PubMed Web of Science ®Google Scholar
• Ferguson MS , LemoineNR, WangY. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv. Virol.2012, 805629 (2012).
   PubMedGoogle Scholar
• Hemminki O , DiaconuI, CerulloVet al. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol. Ther.20(9), 1821–1830 (2012).
   PubMed Web of Science ®Google Scholar
• Koski A , BramanteS, KiparAet al. Biodistribution analysis of oncolytic adenoviruses in patient autopsy samples reveals vascular transduction of noninjected tumors and tissues. Mol. Ther.23(10), 1641–1652 (2015).
   PubMed Web of Science ®Google Scholar
• Russell SJ , PengK-W, BellJC. Oncolytic virotherapy. Nat. Biotechnol.30(7), 658 (2012).
   PubMed Web of Science ®Google Scholar
• Kulu Y , DorfmanJD, KuruppuDet al. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther.16(4), 291–297 (2009).
   PubMed Web of Science ®Google Scholar
• Eisenstein S , CoakleyBA, Briley-SaeboKet al. Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res.73(16), 5003–5015 (2013).
   PubMed Web of Science ®Google Scholar
• Mahasa KJ , de PillisL, OuifkiRet al. Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy. Sci. Rep.10(1), 1–13 (2020).
   PubMed Web of Science ®Google Scholar
• Hong S-H , ParkS-J, LeeS, ChoCS, ChoM-H. Aerosol gene delivery using viral vectors and cationic carriers for in vivo lung cancer therapy. Expert Opin. Drug Deliv.12(6), 977–991 (2015).
   PubMed Web of Science ®Google Scholar
• Agarkhedkar S , KulkarniPS, WinstonSet al. Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial. Vaccine32(50), 6791–6797 (2014).
   PubMed Web of Science ®Google Scholar
• Carlisle R , ChoiJ, Bazan-PeregrinoMet al. Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound. J. Natl Cancer Inst.105(22), 1701–1710 (2013).
   PubMed Web of Science ®Google Scholar
• Howard F , MuthanaM. Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. Nanomedicine15(1), 93–110 (2020).
   PubMed Web of Science ®Google Scholar
• Intlekofer AM , ThompsonCB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol.94(1), 25–39 (2013).
   PubMed Web of Science ®Google Scholar
• Zamarin D , RiccaJM, SadekovaSet al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J. Clin. Invest.128(4), 1413–1428 (2018).
   PubMed Web of Science ®Google Scholar
• Fend L , YamazakiT, RemyCet al. Immune checkpoint blockade, immunogenic chemotherapy or IFN-α blockade boost the local and abscopal effects of oncolytic virotherapy. Cancer Res.77(15), 4146–4157 (2017).
   PubMed Web of Science ®Google Scholar
• Liu Z , RavindranathanR, KalinskiPet al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun.8(1), 1–12 (2017).
   PubMedGoogle Scholar
• Engeland CE , GrossardtC, VeinaldeRet al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol. Ther.22(11), 1949–1959 (2014).
   PubMed Web of Science ®Google Scholar
• Kelly KR , EspitiaCM, ZhaoWet al. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia32(1), 230–233 (2018).
   PubMed Web of Science ®Google Scholar
• Bartee MY , DunlapKM, BarteeE. Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy. Cancer Res.77(11), 2952–2963 (2017).
   PubMed Web of Science ®Google Scholar
• Goepfert K , DinsartC, RommelaereJet al. Rational combination of parvovirus H1 with CTLA-4 and PD-1 checkpoint inhibitors dampens the tumor induced immune silencing. Front. Oncol.9 (2019).
   PubMedGoogle Scholar
• Nakashima H , KaurB, ChioccaEA. Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev.21(2–3), 119–126 (2010).
   PubMed Web of Science ®Google Scholar
• Wunder T , SchumacherU, FriedrichRE. Coxsackie adenovirus receptor expression in carcinomas of the head and neck. Anticancer Res.32(3), 1057–1062 (2012).
   PubMed Web of Science ®Google Scholar
• Wang H , LiawY-C, StoneDet al. Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J. Virol.81(23), 12785–12792 (2007).
   PubMed Web of Science ®Google Scholar
• Strauss R , SovaP, LiuYet al. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res.69(12), 5115–5125 (2009).
   PubMed Web of Science ®Google Scholar
• Beyer I , van RensburgR, StraussRet al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res.71(22), 7080–7090 (2011).
   PubMed Web of Science ®Google Scholar
• Fender P , BoussaidA, MezinP, ChroboczekJ. Synthesis, cellular localization, and quantification of penton-dodecahedron in serotype 3 adenovirus-infected cells. Virology340(2), 167–173 (2005).
   PubMed Web of Science ®Google Scholar
• Lu Z-Z , WangH, ZhangYet al. Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells. PLoS Pathog.9(10), (2013).
   Web of Science ®Google Scholar
• Wang H , LiZ-Y, LiuYet al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med.17(1), 96 (2011).
   PubMed Web of Science ®Google Scholar
• Wang H , DucournauC, SaydaminovaKet al. Intracellular signaling and desmoglein 2 shedding triggered by human adenoviruses Ad3, Ad14, and Ad14P1. J. Virol.89(21), 10841–10859 (2015).
   PubMed Web of Science ®Google Scholar
• Yumul R , RichterM, LuZ-Zet al. Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models. Hum. Gene Ther.27(4), 325–337 (2016).
   PubMed Web of Science ®Google Scholar
• Vähä-Koskela M , HinkkanenA. Tumor restrictions to oncolytic virus. Biomedicines2(2), 163–194 (2014).
   PubMedGoogle Scholar
• Pitner R , KimJ, Davis-BergtholdJet al. structure-based Design of JoC-x, a conjugatable tumor tight Junction opener to enhance cancer therapy. Sci. Rep.9(1), 1–13 (2019).
   PubMedGoogle Scholar
• Ebrahimi S , GhorbaniE, KhazaeiMet al. Interferon-mediated tumor resistance to oncolytic virotherapy. J. Cell. Biochem.118(8), 1994–1999 (2017).
   PubMed Web of Science ®Google Scholar
• Moerdyk-Schauwecker M , ShahNR, MurphyAMet al. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology436(1), 221–234 (2013).
   PubMed Web of Science ®Google Scholar
• Stark GR , KerrIM, WilliamsBRGet al. How cells respond to interferons. Annu Rev. Biochem.67, 227–264 (1998).
   PubMed Web of Science ®Google Scholar
• Jackson JD , MarkertJM, LiLet al. STAT1 and NF-κB inhibitors diminish basal interferon-stimulated gene expression and improve the productive infection of oncolytic HSV in MPNST cells. Mol. Cancer Res.14(5), 482–492 (2016).
   PubMed Web of Science ®Google Scholar
• Cataldi M , ShahNR, FeltSA, GrdzelishviliVZ. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. Virology485, 340–354 (2015).
   PubMed Web of Science ®Google Scholar
• Paglino JC , vanden Pol AN. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J. Virol.85(18), 9346–9358 (2011).
   PubMed Web of Science ®Google Scholar
• Ruotsalainen JJ , KaikkonenMU, NiittykoskiMet al. Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model. Gene Ther.22(1), 65–75 (2015).
   PubMed Web of Science ®Google Scholar
• Echchgadda I , ChangT-H, SabbahAet al. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. BMC Cancer11(1), 43 (2011).
   PubMedGoogle Scholar
• Berchtold S , LampeJ, WeilandTet al. Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis. J. Virol.87(6), 3484–3501 (2013).
   PubMed Web of Science ®Google Scholar
• Liikanen I , MonsurròV, AhtiainenLet al. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol. Ther.19(10), 1858–1866 (2011).
   PubMed Web of Science ®Google Scholar
• Hastie E , CataldiM, MoerdykMJet al. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Oncotarget7(38), 61601 (2016).
   PubMedGoogle Scholar
• Dold C , UrbiolaCR, WollmannGet al. Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. Mol. Ther.3, 16021 (2016).
   Web of Science ®Google Scholar
• Kurokawa C , IankovID, GalanisE. A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells. Virus Res.263, 145–150 (2019).
   PubMed Web of Science ®Google Scholar
• Liu Y-P , SuksanpaisanL, SteeleMBet al. Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. Sci. Rep.3, 2375 (2013).
   PubMed Web of Science ®Google Scholar
• Lee JM , GhonimeMG, CassadyKA. STING restricts oHSV replication and spread in resistant MPNSTs but is dispensable for basal ifn-stimulated gene upregulation. Mol. Ther.15, 91–100 (2019).
   Web of Science ®Google Scholar
• WuDUNN D , SpearPG. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol.63(1), 52–58 (1989).
   PubMed Web of Science ®Google Scholar
• Montgomery RI , WarnerMS, LumBJ, SpearPG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell87(3), 427–436 (1996).
   PubMed Web of Science ®Google Scholar
• Shukla D , LiuJ, BlaiklockPet al. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell99(1), 13–22 (1999).
   PubMed Web of Science ®Google Scholar
• Geraghty RJ , KrummenacherC, CohenGHet al. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science.280(5369), 1618–1620 (1998).
   PubMed Web of Science ®Google Scholar
• Warner MS , GeraghtyRJ, MartinezWMet al. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology246(1), 179–189 (1998).
   PubMed Web of Science ®Google Scholar
• Fu X , TaoL, WangP-Yet al. Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget9(30), 21348 (2018).
   PubMedGoogle Scholar
• Lee NH , KimM, OhSYet al. Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment. Oncotarget8(1), 1213 (2017).
   PubMedGoogle Scholar
• Milewska A , KindlerE, VkovskiPet al. APOBEC3-mediated restriction of RNA virus replication. Sci. Rep.8(1), 1–12 (2018).
   PubMedGoogle Scholar
• Roberts SA , LawrenceMS, KlimczakLJet al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet.45(9), 970 (2013).
   PubMed Web of Science ®Google Scholar
• Walker BA , WardellCP, MurisonAet al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun.6(1), 1–11 (2015).
   Google Scholar
• Huff AL , WongthidaP, KottkeTet al. APOBEC3 mediates resistance to oncolytic viral therapy. Mol. Ther.11, 1–13 (2018).
   Web of Science ®Google Scholar